Description: View the Archive Spring 2017 Group and Health Core Exam Canada.

Description: View the ive Archive Fall 2017: Retirement Plan Investment and Risk Management Exam.

Description: Actuaries are increasingly being asked to incorporate Economic Scenario Generators into their work. Whether it be a Risk Neutral model for pricing or a Real-World version for Economic Capital modelling, using these tools can help produce a much more robust analysis. Unfortunately, these models and their underpinnings are also very complicated, which can lead to confusion. Come watch the presenters try to demystify some of this. In particular, they will address the following questions: • What is the difference between Real-World and Risk Neutral scenarios? • When should I use one or the other? • How are these models calibrated? • What are some of the misconceptions about these models? At the conclusion of the session, attendees will be able to: • Explain the difference between Real-World and a Risk Neutral scenarios • Understand the appropriate usage of both • Identify some of the calibration questions that go into developing an appropriate set of scenarios • Avoid some of the common misconceptions about these scenarios

Description: Product complexity, the services provided by distributors, their method of obtaining clients, and their relationship to insurers all affect the characteristics of in force membership. Selecting the distribution channel(s) for a product can have a significant effect on overall profitability. Total sales, acquisition costs, anti-selection/quality of business, persistency, control over market targeting, etc., will vary based on the initial strategy decisions and future adjustments. Gaining a high-level understanding of distribution channels will help develop an appreciation for the importance of these decisions.

Description: Our understanding of the biology of aging is increasing rapidly, creating insight into how and why any organism is aging. Some of the mechanisms by which the process of aging occurs in mammals are sufficiently well understood that clinical trials targeting them in humans to improve later life health and longevity are now being undertaken. Translating results seen in mammals to humans has the potential to increase life expectancy far beyond what we have seen historically. Come explore the current state and outlook of research.

Description: How do we take a Minimum Viable Products (MVP) approach to launch new insurance products? Join this moderated discussion and focus on three key development aspects: Distribution, Systems, and the design and pricing of the Insurance product itself. Come discuss reasons to choose an MVP approach and how it solves many of the product launch challenges.

Description: The article discusses the continued popularity of indexed UL insurance and possible reasons why a company's actual indexed UL earnings may be below their original pricing expectations for the product. The article discusses several key items that may be the source of that underperformance (e.g., hedge ineffectiveness, policyholder behavior) and the need to monitor earnings and perform analyses to better understand those potential sources.

Description: An analysis of US population mortality trends and the impact of COVID.

Description: Valerie Tsang and Jessica Kirkwood are both senior consultants with Ernst & Young LLP (EY UK) and Ernst & Young LLP (EY US) respectively, who also have something else in common—they both have recently moved to a new country and are now immersed in a different market. Here, they discuss the quick-changing landscape of actuarial work and regulations and the importance of being aware of the key issues both in the countries they work in and globally, as well as some of the differences they have seen between the UK and US markets.

Description: The chairperson for the marketing and distribution section discusses the section welcome call and outline future topics and themes for the year head.